??????-To The Moon - Tiger Brokers Online Investing Community - To The Moon

Like
Comment
Favorite

森林之心
2021-06-07

??????

科济药业-B今起招股，一手入场费约16565.26港元

科济药业-B(02171)6月7日-6月10日招股。公司发行9474.7万股。其中90%为国际发售，10%为公开发售，另有不超过15%超额配股权。每股发行价29.6-32.8港元(单位下同)；每手50

科济药业-B今起招股，一手入场费约16565.26港元

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Like

Report

Comment

Top
Latest

empty

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":114956592,"tweetId":"114956592","gmtCreate":1623044767316,"gmtModify":1704194938776,"author":{"id":3583532696513131,"idStr":"3583532696513131","authorId":3583532696513131,"authorIdStr":"3583532696513131","name":"森林之心","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>??????</p></body></html>","htmlText":"<html><head></head><body><p>??????</p></body></html>","text":"??????","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/114956592","repostId":1111166557,"repostType":4,"repost":{"id":"1111166557","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1623030069,"share":"https://www.laohu8.com/m/news/1111166557?lang=&edition=full","pubTime":"2021-06-07 09:41","market":"hk","language":"zh","title":"科济药业-B今起招股，一手入场费约16565.26港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1111166557","media":"老虎资讯综合","summary":"科济药业-B(02171)6月7日-6月10日招股。公司发行9474.7万股。其中90%为国际发售，10%为公开发售，另有不超过15%超额配股权。每股发行价29.6-32.8港元(单位下同)；每手50","content":"<p>科济药业-B(02171)6月7日-6月10日招股。公司发行9474.7万股。其中90%为国际发售，10%为公开发售，另有不超过15%超额配股权。每股发行价29.6-32.8港元(单位下同)；每手500股，预期6月18日上市。</p><p><img src=\"https://static.tigerbbs.com/f9ffdd89cc2ae2a0349c2756dd3e3c43\" tg-width=\"600\" tg-height=\"566\" referrerpolicy=\"no-referrer\"></p><p><b>申购阶梯：</b></p><p>每手200股，入场费16,565.26港元。</p><p>乙组门槛为20万股，申购所需资金约6,626,105.12港元。</p><p><img src=\"https://static.tigerbbs.com/b0daf28231122d9f7e2ebbe6e14c9b64\" tg-width=\"685\" tg-height=\"600\" referrerpolicy=\"no-referrer\"></p><p>公司是生物制药公司。公司目前并无获批准商业化销售的产品及尚未从产品销售产生任何收益。2019年-2020年公司研发开支分别为人民币2.1亿元及2.8亿元。</p><p>公司共引入9名基石投资者，基石认购占全球发售比重的约60%，以下限价格计算，基石占比63.64%。其中，公司紧密联系人LAV实体认购5000万美元，新华保险旗下新华资本认购4500万美元，东方证券旗下睿远认购3000万美元，WT基金、广发基金、Dymon亚洲资本、常春藤、华泰证券旗下的南方基金等为基石。</p><p><img src=\"https://static.tigerbbs.com/4cc47fa62c5af542ad22afb4472f5af6\" tg-width=\"780\" tg-height=\"538\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>科济药业-B今起招股，一手入场费约16565.26港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n科济药业-B今起招股，一手入场费约16565.26港元\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2021-06-07 09:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>科济药业-B(02171)6月7日-6月10日招股。公司发行9474.7万股。其中90%为国际发售，10%为公开发售，另有不超过15%超额配股权。每股发行价29.6-32.8港元(单位下同)；每手500股，预期6月18日上市。</p><p><img src=\"https://static.tigerbbs.com/f9ffdd89cc2ae2a0349c2756dd3e3c43\" tg-width=\"600\" tg-height=\"566\" referrerpolicy=\"no-referrer\"></p><p><b>申购阶梯：</b></p><p>每手200股，入场费16,565.26港元。</p><p>乙组门槛为20万股，申购所需资金约6,626,105.12港元。</p><p><img src=\"https://static.tigerbbs.com/b0daf28231122d9f7e2ebbe6e14c9b64\" tg-width=\"685\" tg-height=\"600\" referrerpolicy=\"no-referrer\"></p><p>公司是生物制药公司。公司目前并无获批准商业化销售的产品及尚未从产品销售产生任何收益。2019年-2020年公司研发开支分别为人民币2.1亿元及2.8亿元。</p><p>公司共引入9名基石投资者，基石认购占全球发售比重的约60%，以下限价格计算，基石占比63.64%。其中，公司紧密联系人LAV实体认购5000万美元，新华保险旗下新华资本认购4500万美元，东方证券旗下睿远认购3000万美元，WT基金、广发基金、Dymon亚洲资本、常春藤、华泰证券旗下的南方基金等为基石。</p><p><img src=\"https://static.tigerbbs.com/4cc47fa62c5af542ad22afb4472f5af6\" tg-width=\"780\" tg-height=\"538\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/1843fd3dbead1ca6cb2ae7c39aeb579a","relate_stocks":{"02171":"科济药业-B"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111166557","content_text":"科济药业-B(02171)6月7日-6月10日招股。公司发行9474.7万股。其中90%为国际发售，10%为公开发售，另有不超过15%超额配股权。每股发行价29.6-32.8港元(单位下同)；每手500股，预期6月18日上市。申购阶梯：每手200股，入场费16,565.26港元。乙组门槛为20万股，申购所需资金约6,626,105.12港元。公司是生物制药公司。公司目前并无获批准商业化销售的产品及尚未从产品销售产生任何收益。2019年-2020年公司研发开支分别为人民币2.1亿元及2.8亿元。公司共引入9名基石投资者，基石认购占全球发售比重的约60%，以下限价格计算，基石占比63.64%。其中，公司紧密联系人LAV实体认购5000万美元，新华保险旗下新华资本认购4500万美元，东方证券旗下睿远认购3000万美元，WT基金、广发基金、Dymon亚洲资本、常春藤、华泰证券旗下的南方基金等为基石。","news_type":1},"isVote":1,"tweetType":1,"viewCount":45,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":6,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}